Detalhe da pesquisa
1.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
N Engl J Med
; 386(18): 1687-1699, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35334197
2.
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
Br J Dermatol
; 188(2): 218-227, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763878
3.
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
Br J Dermatol
; 189(6): 666-673, 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708254
4.
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Br J Dermatol
; 187(3): 338-352, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484697
5.
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
J Am Acad Dermatol
; 85(4): 847-853, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090959
6.
The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms.
J Investig Dermatol Symp Proc
; 20(1): S71-S77, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33099392
7.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
J Am Acad Dermatol
; 83(3): 839-846, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32344071
8.
An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis.
Acta Derm Venereol
; 100(19): adv00344, 2020 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33236124
9.
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
J Am Acad Dermatol
; 80(1): 70-79.e3, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29969700
10.
Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: results from BRAVE-AA1 and BRAVE-AA2 studies.
J Am Acad Dermatol
; 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38852742
11.
Development and validation of a new method for potential use of Psoriasis Area and Severity Index in teledermatology.
Australas J Dermatol
; 62(1): e114-e117, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33247832
12.
Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
JAMA Dermatol
; 159(9): 970-976, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556146
13.
Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2.
Dermatol Ther (Heidelb)
; 13(12): 3181-3191, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740856
14.
Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.
Dermatol Ther (Heidelb)
; 13(12): 3209-3220, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37991697
15.
Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
J Dermatolog Treat
; 34(1): 2227299, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381691
16.
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Am J Clin Dermatol
; 24(3): 443-451, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36855020
17.
A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults.
J Drugs Dermatol
; 10(7): 744-9, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21720656
18.
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
Dermatol Ther (Heidelb)
; 10(4): 663-670, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415575
19.
"'You lose your hair, what's the big deal?' I was so embarrassed, I was so self-conscious, I was so depressed:" a qualitative interview study to understand the psychosocial burden of alopecia areata.
J Patient Rep Outcomes
; 4(1): 76, 2020 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914253
20.
Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata.
Am J Clin Dermatol
; 21(5): 725-732, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32803546